Definition of responder: Introduction

Research output: Contribution to journalArticle

Abstract

Availability of multiple disase modifiyng treatments in multiple sclerosis requires the definition of criteria to classify the response to individual treatments, to open the possibility to substitute a drug with another potentially effective drugs in case of treatment failure or to add a second treatment if the first is classified as partially effective. Because of the large inter and intra-individual variability of the disease evolution such a classification is frequently difficult. Different clinical and magnetic resonance imaging (MRI) parameters have been proposed. Measures of disease activity, attacks and active MRI lesions, are ore suitable, particularly in the remitting phase of the disease.

Original languageEnglish
JournalNeurological Sciences
Volume29
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Magnetic Resonance Imaging
Treatment Failure
Pharmaceutical Preparations
Multiple Sclerosis

Keywords

  • Escalating therapy
  • Immunomodulary treatments
  • Immunosuppressive treatments
  • Induction therapy

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Definition of responder : Introduction. / Comi, Giancarlo.

In: Neurological Sciences, Vol. 29, No. SUPPL. 2, 09.2008.

Research output: Contribution to journalArticle

@article{76a74c06ce3f4e61a88a040f67aa6168,
title = "Definition of responder: Introduction",
abstract = "Availability of multiple disase modifiyng treatments in multiple sclerosis requires the definition of criteria to classify the response to individual treatments, to open the possibility to substitute a drug with another potentially effective drugs in case of treatment failure or to add a second treatment if the first is classified as partially effective. Because of the large inter and intra-individual variability of the disease evolution such a classification is frequently difficult. Different clinical and magnetic resonance imaging (MRI) parameters have been proposed. Measures of disease activity, attacks and active MRI lesions, are ore suitable, particularly in the remitting phase of the disease.",
keywords = "Escalating therapy, Immunomodulary treatments, Immunosuppressive treatments, Induction therapy",
author = "Giancarlo Comi",
year = "2008",
month = "9",
doi = "10.1007/s10072-008-0938-x",
language = "English",
volume = "29",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Definition of responder

T2 - Introduction

AU - Comi, Giancarlo

PY - 2008/9

Y1 - 2008/9

N2 - Availability of multiple disase modifiyng treatments in multiple sclerosis requires the definition of criteria to classify the response to individual treatments, to open the possibility to substitute a drug with another potentially effective drugs in case of treatment failure or to add a second treatment if the first is classified as partially effective. Because of the large inter and intra-individual variability of the disease evolution such a classification is frequently difficult. Different clinical and magnetic resonance imaging (MRI) parameters have been proposed. Measures of disease activity, attacks and active MRI lesions, are ore suitable, particularly in the remitting phase of the disease.

AB - Availability of multiple disase modifiyng treatments in multiple sclerosis requires the definition of criteria to classify the response to individual treatments, to open the possibility to substitute a drug with another potentially effective drugs in case of treatment failure or to add a second treatment if the first is classified as partially effective. Because of the large inter and intra-individual variability of the disease evolution such a classification is frequently difficult. Different clinical and magnetic resonance imaging (MRI) parameters have been proposed. Measures of disease activity, attacks and active MRI lesions, are ore suitable, particularly in the remitting phase of the disease.

KW - Escalating therapy

KW - Immunomodulary treatments

KW - Immunosuppressive treatments

KW - Induction therapy

UR - http://www.scopus.com/inward/record.url?scp=53649087700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53649087700&partnerID=8YFLogxK

U2 - 10.1007/s10072-008-0938-x

DO - 10.1007/s10072-008-0938-x

M3 - Article

C2 - 18690493

AN - SCOPUS:53649087700

VL - 29

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 2

ER -